Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs

被引：8
|
作者：
Simoens S. [1 ]
Cassiman D. [2 ]
Picavet E. [1 ]
Dooms M. [3 ]
机构：
[1] Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, 3000 Leuven, Onderwijs en Navorsing 2
[2] Department of Hepatology, University Hospital Leuven, Leuven
[3] Hospital Pharmacy, University Hospital Leuven, Leuven
来源：
Drugs & Therapy Perspectives | 2011年 / 27卷 / 10期
关键词：
Orphan Drug; Healthcare Payer; Orphan Designation; Belgian Hospital; Hospital Price;
D O I：
10.2165/11601640-000000000-00000
中图分类号：
学科分类号：
摘要：
Hospital purchase prices substantially exceed compounding production costs in Belgium for selected orphan drugs that had low costs of research and development and market access procedures. As a result, healthcare payers seem to be paying too much for these orphan drugs and there are arguments for price reductions. Pharmacies can consider compounding, rather than purchasing, these orphan drugs. © 2011 Adis Data Information BV. All rights reserved.
引用
收藏
页码：24 / 26
页数：2
相关论文
共 50 条
  • [41] Rare or orphan diseases. A review study
    Horna, Ener Mantilla
    Fernande, Johel Osorio
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2025, 23
  • [42] FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES
    Szegedi, Marta
    Kosztolanyi, Gyoergy
    Boncz, Imre
    Molnar, Maria Judit
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2016, 69 (1-2): : 37 - 45
  • [43] Spending on and beneficiaries of orphan cancer drugs for ultra-rare, rare, and common diseases
    Michaeli, J. C.
    Michaeli, C. T.
    Michaeli, D. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S927 - S928
  • [44] EXPERTS CONSENSUS ON THE FUTURE OF RARE DISEASES CARE AND ORPHAN DRUGS ACCESS IN SPAIN: A DELPHI STUDY
    Paz, S.
    Torrent, J.
    Poveda, J. L.
    Perez, J.
    Moreno, J. L.
    Martin, A.
    Gonzalez, L.
    Cruz, J.
    Comellas, M.
    Abaitua, I
    Urcelay, J.
    VALUE IN HEALTH, 2015, 18 (07) : A679 - A679
  • [45] Orphan Drugs for Rare Diseases: Debating the Challenges of Health Commissioning in the UK
    Ticehurst, Flo
    JOURNAL OF MEDICAL GENETICS, 2008, 45 : S103 - S103
  • [46] CRITERIA TO DEFINE RARE DISEASES AND ORPHAN DRUGS: SYSTEMATIC LITERATURE REVIEW
    Abozaid, G.
    Kerr, K.
    McKnight, A.
    Al-Omar, H.
    VALUE IN HEALTH, 2022, 25 (12) : S264 - S264
  • [47] Balancing economic, ethical and equity concerns in orphan drugs and rare diseases
    McCabe, Christopher
    EJHP PRACTICE, 2010, 16 (04): : 22 - 25
  • [48] EVOLUTION OF THE UTILIZATION OF THE AIFA 5% FUND FOR ORPHAN DRUGS AND RARE DISEASES
    Tartarelli, F.
    Viola, V.
    Lidonnici, D.
    Marcellusi, A.
    VALUE IN HEALTH, 2023, 26 (12) : S259 - S259
  • [49] Criteria to define rare diseases and orphan drugs: a systematic review protocol
    Abozaid, Ghada Mohammed
    Kerr, Katie
    McKnight, Amy
    Al-Omar, Hussain A.
    BMJ OPEN, 2022, 12 (07):
  • [50] VALUE ASSESSMENT OF ORPHAN DRUGS FOR TREATMENT OF RARE DISEASES: A SYSTEMATIC REVIEW
    Lockhart, C. M.
    Hansen, R. N.
    VALUE IN HEALTH, 2016, 19 (03) : A79 - A79
12345